Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued to investors on Friday, March 9th. They presently have a $253.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $256.00. Wedbush’s price objective points to a potential upside of 302.67% from the stock’s current price. Wedbush also issued estimates for Intercept Pharmaceuticals’ FY2021 earnings at $10.38 EPS and FY2022 earnings at $21.42 EPS.
Several other analysts have also commented on ICPT. Leerink Swann reaffirmed a “hold” rating and set a $60.00 target price on shares of Intercept Pharmaceuticals in a report on Tuesday, November 28th. ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 target price on the stock. Finally, Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, December 21st. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $128.75.
Shares of ICPT stock traded up $2.83 during mid-day trading on Friday, reaching $62.83. The stock had a trading volume of 1,024,069 shares, compared to its average volume of 854,768. The company has a debt-to-equity ratio of 21.71, a quick ratio of 4.31 and a current ratio of 4.31. The firm has a market capitalization of $1,548.62, a PE ratio of -4.37 and a beta of -1.81. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $135.59.
Institutional investors and hedge funds have recently modified their holdings of the business. DSC Advisors L.P. acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $204,000. Amalgamated Bank acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $209,000. Virtu Financial LLC acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $234,000. Oppenheimer & Co. Inc. grew its holdings in Intercept Pharmaceuticals by 145.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 2,833 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $331,000. 74.27% of the stock is currently owned by institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.